Clinical Trial Update: Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers [Phase 1]

View source ↗

Summary

Phase Ib trial evaluating adagrasib (KRAS G12C inhibitor) in combination with olaparib in KRAS G12C-mutated advanced solid tumors, focusing on gynecologic, brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gynecologic Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• KRAZATI (adagrasib)
• Lynparza (olaparib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancers | Phase 1 | Status: TERMINATED